Related Experiment Video
Updated: Apr 19, 2026
Author Spotlight: Advancements and Challenges in β-Cells Differentiation from Pluripotent Stem Cells
Published on: February 2, 2024
An optimized protocol for efficient derivation of pancreatic islets from multiple human pluripotent stem cell lines
Siqin Wu1, Shivam Chandel2, Galyna Bryzgalova3
1Department of Clinical Sciences, Intervention and Technology, Karolinska Institutet, 171 77 Stockholm, Sweden; Gynecology and Reproductive Medicine, Karolinska Universitetssjukhuset, 141 86 Stockholm, Sweden; Spiber Technologies AB, AlbaNova University Center, 106 91 Stockholm, Sweden.
A new protocol generates functional stem cell-derived islets (SC-islets) for type 1 diabetes (T1D) cell therapy. These SC-islets are free of non-endocrine cells and restore normal glycemic control after transplantation.
Area of Science:
- Regenerative Medicine
- Endocrinology
- Stem Cell Biology
Background:
- Cell therapy for type 1 diabetes (T1D) requires functional pancreatic islets.
- Current stem cell-derived islet (SC-islet) protocols yield immature islets with non-endocrine cells.
Purpose of the Study:
- To develop a robust protocol for generating highly functional SC-islets from human pluripotent stem cells (hPSCs).
- To produce SC-islets suitable for T1D cell therapy, free of non-endocrine cells.
Main Methods:
- Optimized differentiation of hPSCs to endocrine progenitors (EPs) using laminin-521.
- Shortened pancreatic progenitor (PP) stage and utilized EP self-aggregation to remove unwanted cells.
- Suspension culture for SC-islet maturation and in vitro/in vivo functional assessment.
Main Results:
- A robust protocol generated functional SC-islets from all tested hPSC lines.
- SC-islets demonstrated strong glucose responsiveness in vitro.
- Transplanted SC-islets matured, restored glycemic control in diabetic mice, and were devoid of non-endocrine cells.
Conclusions:
- The developed protocol enables the production of highly functional, pure SC-islets.
- This advancement is crucial for the success of T1D cell therapy.
- The protocol offers a promising strategy for generating clinical-grade islets.
